Mylan's (MYL) Reassuring Quarter Drives PT To $39 Ahead Of Generic Advair - Mizuho

Mizuho Securities analyst, Irina Koffler, reiterated her Neutral rating on shares of Mylan (NASDAQ: MYL) and raised her price target to $39 from $37 after the company reported comforting 3Q:18 results attributed to $300M in high margin new product sales, and reiterated its 2018 guidance. N. America sales beat expectations and F/X drove the international miss.

The analyst stated "Management still expects approval of a substitutable generic Advair imminently, and is in final labeling discussions with FDA. We pushed Advair estimates to December, with minimal contribution to 2018".

For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.

Shares of Mylan closed at $34.00 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Oppenheimer Reiterates Outperform Rating on NVIDIA (NVDA) Into EPS
• TD Cowen Reiterates Buy Rating on Broadcom Limited (AVGO), neutral into the print